欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日韩亚洲欧美中文高清在线 | 精品sm亚洲av无码sm | 亚洲制服丝袜精品久久 | 国产最爽的乱淫视频国语对白 | 粉嫩白丝jk被啪到深处流水 | 牛牛综合影院永久入口 | 国产h视频在线观看免费 | 国产精品免费一级在线观看 | 欧美日韩一区二区三 | 国产免费久久久久久免费看 | 欧美日韩国产成人综合在线影院 | 精品激情综合久久 | 久久精品亚洲男人的天堂 | 国产福利91精品一区二区三区 | 日本一道综合久久aⅴ免费 日本一二三区dvd视频 | 久久伊人热 | 夫妻性生活影片国内 | 在线看亚洲无码视频专区 | 亚洲欧美一级夜夜爽w | 国产免费av片 | 成熟女人毛片www | 91丝袜白浆高潮潮喷 | 无码专区在 | 一本色道久久99一综合 | 国产亚洲精品在天 | 欧美男女插插插的 | 91天天摸天天 | 亚洲欧洲另类图片综合专区 | 熟女少妇丰满一区二区 | 最新免费电影大全 | 日本国产三级精品三级在线观看 | 亚洲熟女| 国产精品美女久久久久av爽心 | 国产又粗又大 | 成人国产亚洲日本在线 | 丰满人妻熟妇乱又伦精品视 | 国产欧美日韩久久久 | 在线播放国产1区 | 国产精品欧美福利久久 | 免费电影高清在线观看 | 午夜精品国产欧美日韩久久久久 |